Sanofi celebrates EU approvals
February 5, 2013Sales and Marketing Lyxumia, Sanofi, Zaltrap, diabetes
Sanofi is celebrating after diabetes treatment Lyxumia (lixisenatide) and metastatic colorectal cancer (mCRC) drug Zaltrap received authorisation in Europe. The …
Recipharm appoints Hans Lennernäs to operating Board
February 5, 2013Manufacturing and Production, Research and Development, Sales and Marketing Recipharm
Recipharm Pharmaceutical Development AB has announced the appointment of Dr Hans Lennernäs to the company’s Board of directors. Lennernäs is …
GP concern over GMC guidance
February 5, 2013Sales and Marketing ABPI, GMC, GP, NHS
The ABPI has ‘warmly’ welcomed the new prescribing guidance from the General Medical Council – but GPs are far from …
SFDA publishes high-risk excipients list
February 5, 2013Manufacturing and Production China, GMP, SFDA
China’s State Food and Drug Administration (SFDA) has published a list of 28 excipients which are considered high-risk and therefore …
Langland triumph again at PM Society Ad Awards
February 4, 2013Medical Communications, Sales and Marketing awards. langland, pm society
Langland Advertising swept the board for the third time in four years at the PM Society Advertising Awards, held on …
Facility of the year: 2013 winners announced
February 4, 2013Manufacturing and Production Biogen, MedImmune, Merck, Novartis, Roche
Three US and three European manufacturing plants have been selected as category winners for the annual Facility of the Year …
Hunt pledges ‘paperless NHS’
February 4, 2013Sales and Marketing DH, Hunt, NHS, paperless
Health secretary Jeremy Hunt has put his head on the block by pledging that moves towards a ‘paperless NHS’ will …
USP rejects appeals on elemental impurities update
February 4, 2013Manufacturing and Production USP
The US Pharmacopeial Convention (USP) has rejected an appeal by drugmakers and suppliers of pharmaceutical ingredients to postpone publication of …
Pharma manufacturing news in brief
February 4, 2013Manufacturing and Production ACS, Amcor, Beanne, Iogen Bio-products, Novozymes, Pluristem
Facility investments from Amcor and Pluristem, Beanne Chemical falls foul of FDA inspectors, Novozymes acquisition plus a green chemistry app.
Survey shock for pharma
February 4, 2013Medical Communications, Research and Development, Sales and Marketing Cancer, PACE, lilly, pharma, research
A survey released to tie in with today’s World Cancer Day finds that most people feel pharma companies see cancers …
NHS Commissioning Board executive departs
February 4, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CB, Dalton, NHS
The NHS Commissioning Board has announced the forthcoming departure of its chief operating officer and deputy chief executive. Ian Dalton …
Lewisham A&E spared axe
February 1, 2013Sales and Marketing Hunt, Lewisham, Miliband, NHS
The government’s threat to close Lewisham Hospital’s A&E unit has been lifted after health secretary Jeremy Hunt decided to cut …
NICE rejects Forxiga
February 1, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, NICE, diabetes
NICE has given the thumbs-down to AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga. The drug was approved …
Novo Nordisk creates four senior vice presidents
February 1, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk
Novo Nordisk has promoted four corporate vice presidents within its ranks into senior vice presidents. The following members of the US …
GSK slams Guardian article
January 31, 2013Sales and Marketing Avandia, FDA, GSK, Guardian
GlaxoSmithKline has slammed an article about its controversial diabetes treatment Avandia in The Guardian newspaper, saying that some of it …
NHS expertise sold abroad
January 31, 2013Sales and Marketing NHS, UK, government, outsourcing
The government has set up an organisation which will seek to maximise revenue from foreign firms and governments for the …
Lilly hit by Zyprexa losses
January 30, 2013Sales and Marketing antipsychotic, lilly, zyprexa
The loss of exclusivity on Eli Lilly’s blockbuster antipsychotic Zyprexa hit the company hard in 2012, with the firm’s overall …
EMA starts contraceptive safety review
January 30, 2013Manufacturing and Production, Sales and Marketing EMA, PRAC, VTE, contraception
Europe’s health regulator is to examine the safety of newer forms of contraceptive pills following concerns over potential health risks …
Merck signs lupus research deal
January 30, 2013Research and Development, Sales and Marketing Feinstein, Merck Serono, SLE
Merck Serono and the Feinstein Institute for Medical Research in New York are to collaborate on antibodies to treat systemic …
Oxyrane brings on board senior team
January 30, 2013Manufacturing and Production, Research and Development, Sales and Marketing Oxyrane, biotech
UK biotech firm Oxyrane has expanded to the US and made a number of senior appointments. The privately-owned Manchester-based company’s first …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
